Diabetes and Colorectal Cancer Risk and Survival According to Tumor Immunity Status
Journal of Clinical Oncology · 10.09.2025 · 43 (26) · 2930-2941
DOI: 10.1200/jco-25-00148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.09.2025. Verfasst von Durgesh Wankhede und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Diabetes Mellitus, Type 2, Lymphocytes, Tumor-Infiltrating. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
PURPOSE Type 2 diabetes (T2D) has been associated with an increased risk of colorectal cancer (CRC) and poorer survival outcomes. However, the role of tumor immune status in influencing these relationships remains unclear. METHODS We conducted a population-based matched case-control study (n = 4,724) with prospective long-term follow-up of CRC cases (n = 2,321; median follow-up, 9.5 years). Tumor immune status was assessed using an immune cell score (ICS), derived from CD3 + and CD8 + T-cell densities measured at the invasive margin and tumor core of resected specimens. ICS was stratified into high (ICS Hi ), intermediate (ICS Int ), and low (ICS Low ) immune infiltration on the basis of standard cutoffs (25% and 70%). Multivariable logistic regression estimated CRC risk, whereas time-dependent Cox regression evaluated survival outcomes. Primary end points included CRC-specific survival and disease-free survival (DFS). RESULTS The association between T2D and CRC risk differed significantly by ICS ( P for heterogeneity = .02). T2D was associated with an increased risk of CRC (odds ratio [OR], 1.39 [95% CI, 1.17 to 1.66]), particularly for ICS Low (OR, 1.80 [95% CI, 1.35 to 2.39]) and ICS Int subtypes (OR, 1.42 [95% CI, 1.17 to 1.66]), but not for ICS Hi CRC subtype (OR, 1.16 [95% CI, 0.88 to 1.52]). Patients with T2D with ICS Low tumors showed poorer CRC-specific survival (hazard ratio [HR], 1.99 [95% CI, 1.30 to 3.05]) and DFS (HR, 1.53 [95% CI, 1.05 to 2.26]) than those without T2D, but not for ICS Int and ICS Hi CRC subtypes. Patients with T2D showed inferior overall and non–cancer-related survival regardless of immune subtypes. CONCLUSION T2D disproportionately affects CRC risk and survival in tumors with low immune infiltration, suggesting a continuum of T2D's impact from tumorigenesis to prognosis, through systemic and tumor-specific immune modulation. These findings highlight the need for precision prevention strategies integrating metabolic and immune-based interventions to mitigate CRC burden in patients with T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Faculty of Medicine, University of Heidelberg, Heidelberg, Germany.
- Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
- Department of Translational Immunotherapy (D240), German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Helmholtz Institute for Translational Oncology, Mainz, Germany.
- Department of Applied Tumor Biology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
ORCID-Profile: Durgesh Wankhede, Niels Halama, Michael Hoffmeister
Zitieren
APA
Wankhede, D., Halama, N., Kloor, M., Brenner, H., & Hoffmeister, M. (2025). Diabetes and Colorectal Cancer Risk and Survival According to Tumor Immunity Status. Journal of Clinical Oncology, 43(26), 2930-2941. https://doi.org/10.1200/jco-25-00148
Vancouver
Wankhede D, Halama N, Kloor M, Brenner H, Hoffmeister M. Diabetes and Colorectal Cancer Risk and Survival According to Tumor Immunity Status. Journal of Clinical Oncology. 2025;43(26):2930-2941. doi:10.1200/jco-25-00148
BibTeX
@article{Wankhede2025,
author = {Wankhede, Durgesh and Halama, Niels and Kloor, Matthias and Brenner, Hermann and Hoffmeister, Michael},
title = {Diabetes and Colorectal Cancer Risk and Survival According to Tumor Immunity Status},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {26},
pages = {2930--2941},
doi = {10.1200/jco-25-00148}
}
EUVIMED